UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x                              QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2006

 

OR

 

o                                 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number 001-32374

SYMMETRY MEDICAL INC.

 (Exact name of registrant as specified in its charter)

 

Registrants telephone number, including area code (574) 268-2252

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   x No   o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check One)

Large accelerated filer   o           Accelerated filer   x            Non-accelerated filer   o

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes o No x

The number of shares outstanding of the registrant’s common stock as of October 10, 2006 was 35,099,971.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION
Item 1     -	Financial Statements:
	Condensed Consolidated Balance Sheets: As of September 30, 2006 and December 31, 2005
	Condensed Consolidated Statements of Operations: Three and Nine Months Ended September 30, 2006 and October 1, 2005
	Condensed Consolidated Statements of Cash Flows: Nine Months Ended September 30, 2006 and October 1, 2005
	Notes to Condensed Consolidated Financial Statements
Item 2	Management’s Discussion and Analysis of Results of Operations and Financial Condition
Item 3	Quantitative and Qualitative Disclosures about Market Risks
Item 4	Controls and Procedures
PART II OTHER INFORMATION
Item 1	Legal Proceedings
Item 1A	Risk Factors
Item 2	Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities
Item 5	Other Information
Item 6	Exhibits
Signatures

 

2

Symmetry Medical Inc.

Condensed Consolidated Balance Sheets

		September 30,			December 31,
		2006			2005
		(In Thousands, Except Per Share Data)
		(unaudited)
Assets:
Current Assets:
Cash and cash equivalents		$	9,616		$	12,471
Accounts receivables, net		48,278			44,908
Inventories		44,867			38,783
Refundable income taxes		221			185
Deferred income taxes		2,345			1,867
Derivative valuation asset		—			414
Other current assets		2,893			4,032
Total current assets		108,220			102,660
Property and equipment, net		103,350			93,106
Derivative valuation asset		—			170
Goodwill		154,037			124,518
Intangible assets, net of accumulated amortization		33,574			16,327
Other assets		1,061			864
Total Assets		$	400,242		$	337,645
Liabilities and Shareholders’ Equity:
Current Liabilities:
Accounts payable		$	16,494		$	18,983
Accrued wages and benefits		8,815			10,997
Derivative valuation liability		496			—
Other accrued expenses		3,105			2,696
Income tax payable		—			1,241
Deferred income taxes		112			—
Revolving line of credit		4,682			—
Current portion of capital lease obligations		2,846			3,239
Current portion of long-term debt		3,700			1,313
Total current liabilities		40,250			38,469
Deferred income taxes		11,743			11,139
Derivative valuation liability		600			—
Capital lease obligations, less current portion		6,196			8,532
Long-term debt, less current portion		60,500			26,250
Total Liabilities		119,289			84,390
Commitments and contingencies (Note 11)		—			—
Shareholders’ Equity:
Common Stock, $.0001 par value; 72,410 shares authorized; shares issued (September 30, 2006—35,100; December 31, 2005—34,704)		4			3
Additional paid-in capital		271,022			268,973
Retained earnings (deficit)		1,670			(17,378		)
Accumulated other comprehensive income		8,257			1,657
Total Shareholders’ Equity		280,953			253,255
Total Liabilities and Shareholders’ Equity		$	400,242		$	337,645

 

See accompanying notes to condensed consolidated financial statements.

3

Symmetry Medical Inc.

Condensed Consolidated Statements of Operations

		Three Months Ended						Nine Months Ended
		September 30,			October 1,			September 30,			October 1,
		2006			2005			2006			2005
		(In Thousands, Except Per Share Data)
		(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenue		$	60,740		$	67,228		$	195,113		$	201,165
Cost of Revenue		47,093			47,486			144,239			140,593
Gross Profit		13,647			19,742			50,874			60,572
Selling, general, and administrative expenses		7,410			7,455			21,341			21,157
Operating Income		6,237			12,287			29,533			39,415
Other (income) expense:
Interest expense		1,350			635			2,936			2,347
Derivatives valuation (gain)/loss		1,273			(65		)	1,680			(172		)
Other		(203		)	927			(2,482		)	1,811
Income before income taxes		3,817			10,790			27,399			35,429
Income tax expense		826			2,567			8,351			10,922
Net income applicable to common shareholders		$	2,991		$	8,223		$	19,048		$	24,507
Net income applicable to common shareholders per share:
Basic		$	0.09		$	0.24		$	0.55		$	0.73
Diluted		$	0.09		$	0.24		$	0.54		$	0.71
Weighted average common shares and equivalent shares outstanding:
Basic		34,841			34,310			34,796			33,575
Diluted		35,171			34,987			35,162			34,526

 

See accompanying notes to condensed consolidated financial statements.

4

Symmetry Medical Inc.

Condensed Consolidated Statements of Cash Flows

		Nine Months Ended
		September 30,			October 1,
		2006			2005
		(In Thousands)
		(unaudited)			(unaudited)
Operating activities
Net Income		$	19,048		$	24,507
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation		11,786			9,504
Amortization		780			456
Net gain (loss) on sale of assets		(1,219		)	71
Deferred income tax provision		125			374
Excess tax benefit from stock-based compensation		(1,062		)	—
Income tax benefits from exercise of stock options		—			1,199
Stock-based compensation		431			—
Derivative valuation change		1,680			(172		)
Change in operating assets and liabilities:
Accounts receivable		973			(6,449		)
Other assets		2,165			2,212
Inventories		(1,708		)	(2,761		)
Accounts payable		(2,644		)	2,441
Accrued expenses and other		(4,908		)	3,173
Net cash provided by operating activities		25,447			34,555
Investing activities
Purchases of property and equipment		(15,825		)	(31,354		)
Proceeds from the sale of fixed assets		2,434			—
Acquisitions, net of cash received		(54,542		)	—
Net cash used in investing activities		(67,933		)	(31,354		)
Financing activities
Proceeds from bank revolver		63,038			37,065
Payments on bank revolver		(58,595		)	(34,695		)
Issuance of long-term debt		40,000			—
Payments on long-term debt and capital lease obligations		(6,250		)	(6,452		)
Proceeds from the issuance of common and preferred stock, net of expenses		555			11,707
Excess tax benefit from stock-based compensation		1,062			—
Debt issuance costs paid		(355		)	—
Net cash provided by financing activities		39,455			7,625
Effect of exchange rate changes on cash		176			(200		)
Net increase (decrease) in cash and cash equivalents		(2,855		)	10,626
Cash and cash equivalents at beginning of period		12,471			4,849
Cash and cash equivalents at end of period		$	9,616		$	15,475
Supplemental disclosures:
Cash paid for interest		$	3,057		$	1,837
Cash paid for income taxes		$	8,783		$	6,964
Assets acquired under capital leases		$	—		$	283

 

See accompanying notes to condensed consolidated financial statements.

5

Symmetry Medical Inc.

Notes to Condensed Consolidated Financial Statements

(In Thousands, Except Per Share Data)

1.   Basis of Presentation

The condensed consolidated financial statements include the accounts of Symmetry Medical, Inc. and its wholly-owned subsidiaries (collectively referred to as the Corporation), Symmetry Medical USA Inc., Jet Engineering, Inc., Ultrexx, Inc., Riley Medical Inc., Symmetry Medical Everest LLC, Everest Metal International Limited, Symmetry Medical Switzerland SA. (previously named Riley Medical Europe S.A.), Symmetry Medical Cheltenham Limited, Symmetry Medical Polyvac, SAS and Thornton Precision Components Limited. The Corporation is a global supplier of integrated products and services consisting primarily of surgical implants, instruments and cases to orthopedic and other medical device companies.

The condensed consolidated financial statements of the Corporation have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all material adjustments (consisting only of normal recurring adjustments) necessary to present fairly the consolidated financial position of the Corporation, its results of operations and cash flows. The Corporation’s results are subject to seasonal fluctuations. Interim results are not necessarily indicative of results for a full year. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in the Corporation’s Annual Report on Form 10-K for fiscal year 2005.

Certain prior year amounts have been reclassified to conform to the current-year presentation. These reclassifications had no impact on our results of operations or financial position.

The Corporation’s year end is the 52 or 53 week period ending the Saturday closest to December 31. Fiscal year 2006 and 2005 are 52 week years. As such, interim quarters are 13 weeks long ending the Saturday closest to March 31, June 30, or September 30. References in these consolidated financial statements to the three months ended refer to these financial periods, respectively.

On May 1, 2006, the Corporation acquired all of the stock of Riley Medical, Inc., a privately owned company based in Auburn, Maine, and Riley Medical Europe S.A., its Swiss subsidiary (collectively “Riley Medical”).  Refer to note 13 for further discussion.

On August 31, 2006, the Corporation acquired certain assets of Everest Metal Finishing, LLC.  The Corporation also acquired all of the stock of Everest Metal International, Limited.  Collectively Symmetry Medical Everest, LLC and Everest Metal International, Limited are referred to as “Everest Metal.”  Refer to note 13 for further discussion.

2.   Inventories

Inventories consist of the following:

		September 30,			December 31,
		2006			2005
Raw material and supplies		$	11,369		$	7,325
Work-in-process		22,624			23,418
Finished goods		10,874			8,040
		$	44,867		$	38,783

 

6

---

3.   Property and Equipment

Property and equipment, including depreciable lives, consists of the following:

		September 30,			December 31,
		2006			2005
Land		$	1,507		$	1,283
Buildings and improvements (20 to 40 years)		28,399			24,128
Machinery and equipment (5 to 15 years)		116,296			101,437
Office equipment (3 to 5 years)		6,572			5,421
Construction-in-progress		4,948			5,695
		157,722			137,964
Less accumulated depreciation		(54,372		)	(44,858		)
		$	103,350		$	93,106

 

4.   Intangible Assets

Intangible assets subject to amortization consist of technology, non-compete and customer related intangible assets acquired in connection with our acquisitions of Mettis (UK) Limited on June 11, 2003, Riley Medical on May 1, 2006 and Everest Metal on August 31, 2006. These assets ($28,468, net, at September 30, 2006 and $12,656, net, at December 31, 2005) are being amortized using the straight-line method over 4 to 25 years.  The Corporation has $5,106 and $3,671 of indefinite lived intangible assets as September 30, 2006 and December 31, 2005, respectively.

5.   Long-term Debt

In conjunction with the Riley Medical acquisition, the Corporation’s lending arrangements were amended in June 2006 to provide for a new term loan of $40 million, which requires annual principal payments of $300, $400, $400, $11,400 and $27,200 over the next five fiscal years, respectively.  Principal payments have been prepaid through March 2007 on the term loans  In addition, the Corporation’s $40 million revolving credit facility maturity was extended from December 2009 to June 2011.  The financial loan covenants remain unchanged and the Corporation is in compliance with these covenants as of September 30, 2006.

		September 30,			December 31,
		2006			2005
Bank term loan payable in quarterly installments, plus interest at a variable rate (6.625% at September 30, 2006), through December 2009		$	24,500		$	27,563
Bank term loan payable in quarterly installments, plus interest at a variable rate (6.625% at September 30, 2006), through June 2011		39,700			—
Revolving line of credit, due June 2011		—			—
		64,200			27,563
Less current portion		(3,700		)	(1,313		)
		$	60,500		$	26,250

 

6.   New Accounting Pronouncements

In November 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting (SFAS) No. 151, Inventory Costs—an amendment of Accounting Research Bulletin (ARB) No. 43, Chapter 4. The Statement clarifies that abnormal amounts of idle facility expense, freight, handling costs and wasted materials should be recognized as current-period expenses regardless of how abnormal the circumstances. In addition, this Statement requires that the allocation of fixed overheads to the costs of conversion be based upon normal production capacity levels. The Statement is effective for inventory costs incurred during fiscal years beginning after June 15, 2005. This Statement did not have a material effect on the Corporation’s financial position, results of operations or cash flows.

In July 2006, the FASB issued FASB Interpretation No. (FIN) 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109, which clarifies the accounting for uncertainty in tax positions. This Interpretation requires the recognition of a tax position when it is more likely than not that the tax position will be sustained upon examination by relevant taxing authorities, based on the technical merits of the position. The provisions of FIN 48 are effective for the Company on January 1, 2007, with the cumulative effect of the change in accounting principle recorded as an adjustment to opening retained earnings. The Corporation is currently evaluating the impact of adopting FIN 48 on its financial statements.

7

---

7.   Stock-Based Compensation

The Corporation adopted SFAS 123 (revised 2004), Share-Based Payment on January 1, 2006 (SFAS 123R). SFAS 123R, which revised SFAS 123, Accounting for Stock-Based Compensation, superseded APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends SFAS 95, Statement of Cash Flows. Statement 123R requires that all share-based payments to employees, including grants of employee stock options be recognized in the financial statements based upon their fair value. The Corporation had previously followed APB No. 25 in accounting for its stock options and accordingly, no compensation cost had been previously recognized.

The Corporation has adopted SFAS 123R using the modified prospective method. Compensation cost has been recognized for all share-based payments in the consolidated financial statements in 2006 based upon the fair value of the stock or option grant. Prior period results have not been restated.

As a result of adopting SFAS 123R, the Corporation’s income before income taxes and net income for the nine months ended September 30, 2006 are $92 and $55 lower, respectively, than if it had continued to account for share-based compensation under Opinion 25. Basic and diluted earnings per share for the nine months ended September 30, 2006 would not have changed from $0.55 and $0.54, respectively, if the Corporation had not adopted SFAS 123R.

Prior to the adoption of SFAS 123R, the Corporation presented all tax benefits of deductions resulting from the exercise of stock options as operating cash flows in the Consolidated Statements of Cash Flows. SFAS 123R requires the cash flows resulting from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) to be classified as financing cash flows. The $1,062 excess tax benefit for the nine months ended September 30, 2006 that is classified as a financing cash inflow would have been classified as an operating cash inflow if the Corporation had not adopted SFAS 123R.

Statement 123, as amended, required pro forma presentation as if compensation costs had been expensed under the fair value method. For purpose of pro forma disclosure, the estimated fair value of stock options at the grant date is amortized to expense over the vesting period. The following table illustrates the effect on net income and net income per share as if compensation expense had been recognized (in thousands, except for per share amounts):

		Three Months Ended			Nine Months Ended
		October 1, 2005			October 1, 2005
Reported net income applicable to common shareholders		$	8,223		$	24,507
Pro forma stock-based compensation expense (net of tax)		(62		)	(161		)
Stock-based employee compensation recorded (net of tax)		36			54
Adjusted net income		$	8,197		$	24,400
Basic net income per share applicable to common:
Reported net income per share		$	0.24		$	0.73
Stock-based compensation expense (net of tax) per share		—			—
Adjusted net income per share		$	0.24		$	0.73
Diluted net income per share applicable to common:
Reported net income per share		$	0.24		$	0.71
Stock-based compensation expense (net of tax) per share		(0.01		)	—
Adjusted net income per share		$	0.23		$	0.71

 

The compensation cost related to non-vested awards not yet recognized is approximately $33, net, and the weighted average period over which it is expected to be recognized is less than 1 year.  During the nine month period ended September 30, 2006, the Corporation issued 145 shares of common stock through the exercise of stock options, 117 shares of common stock through the exercise of warrants and 10 shares of common stock were issued under the Employee Stock Savings Plan.

8.   Income Taxes

The Corporation’s effective tax rate was 30.5% for the nine month period ended September 30, 2006 as compared to 30.8% for the same periods in 2005. The decrease in the rate from the 2005 effective tax rate was primarily due to recognizing state economic development credits and other tax credits in the second quarter of 2006 and a higher percentage of income coming from lower tax jurisdictions outside of the United States. The 2006 rate would have been lower had the expiration of the Federal research tax credit on December 31, 2005 not occurred.  The United States government has not yet reinstated this tax credit.

8

---

9.   Segment Reporting

The Corporation primarily designs, develops and manufactures implants and related surgical instruments and cases for orthopedic device companies and companies in other medical device markets such as dental, osteobiologic and endoscopy. The Corporation also has a special services business serving primarily aerospace customers, which does not meet the quantitative disclosure requirements of SFAS 131. The Corporation manages its business and operates in a single reportable business segment. Because of the similar economic characteristics of the operations, including the nature of the products, comparable level of FDA regulations, same or similar customers, those operations have been aggregated following the provisions of SFAS 131 for segment reporting purposes.

The Corporation is a multi-national corporation with operations in the United States, the United Kingdom, Ireland, Switzerland and France. As a result, the Corporation’s financial results can be impacted by currency exchange rates in the foreign markets in which the Corporation sells its products. While exposure to variability in foreign currency exists, the Corporation does not believe it is significant to its operations and any variability is somewhat offset through the location of its manufacturing facilities. Revenue is attributed to geographic locations based on the location to which we ship our products.

Revenue from External Customers:

		Three Months Ended						Nine Months Ended
		September 30,			October 1,			September 30,			October 1,
		2006			2005			2006			2005
United States		$	36,080		$	43,631		$	123,253		$	131,060
Ireland		6,237			7,998			19,593			24,288
United Kingdom		10,340			8,843			29,922			23,713
Other foreign countries		8,083			6,756			22,345			22,104
Total net revenues		$	60,740		$	67,228		$	195,113		$	201,165

 

Concentration of Credit Risk:

A substantial portion of the Corporation’s revenue is derived from a limited number of customers. The Corporation’s revenue includes revenue from customers of the Corporation which individually account for 10% or more of revenue as follows:

Quarter ended September 30, 2006—Three customers representing approximately 18%, 14% and 10% of revenue, respectively.

Quarter ended October 1, 2005—Two customers representing approximately 37% and 14% of revenue, respectively.

Following is a summary of the composition by product category of the Corporation’s revenue to external customers. Revenue of the specialty services business is included in the “other” category.

		Three Months Ended						Nine Months Ended
		September 30,			October 1,			September 30,			October 1,
		2006			2005			2006			2005
Implants		$	23,324		$	28,164		$	73,033		$	76,578
Instruments		14,497			20,020			54,107			67,867
Cases		16,623			14,217			47,782			43,822
Other		6,296			4,827			20,191			12,898
Total net revenues		$	60,740		$	67,228		$	195,113		$	201,165

 

9

---

10.   Net Income Per Share

The following table sets forth the computation of earnings per share.

		Three Months Ended						Nine Months Ended
		September 30,			October 1,			September 30,			October 1,
		2006			2005			2006			2005
Net income available to common shareholders		$	2,991		$	8,223		$	19,048		$	24,507
Weighted-average common shares outstanding basic		34,841			34,310			34,796			33,575
Effect of stock options, restricted stock and stock warrants		330			677			366			951
Weighted-average common shares outstanding and assumed conversions		35,171			34,987			35,162			34,526
Net income per share available to common shareholders:
Basic		$	0.09		$	0.24		$	0.55		$	0.73
Diluted		$	0.09		$	0.24		$	0.54		$	0.71

 

11.   Commitments and Contingencies

The Corporation is involved, from time to time, in various contractual, product liability, patent (or intellectual property) and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Corporation, threatened, that the Corporation expects to have a material adverse affect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Corporation currently believes that the disposition of all pending or, to the knowledge of the Corporation threatened, claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Corporation’s consolidated financial condition, results of operations or liquidity.

12.   Comprehensive Income

Comprehensive income is comprised of net income and gains and losses resulting from currency translations of foreign entities. Comprehensive income consists of the following:

		Three Months Ended						Nine Months Ended
		September 30,			October 1,			September 30,			October 1,
		2006			2005			2006			2005
Net Income		$	2,991		$	8,223		$	19,048		$	24,507
Foreign currency translation adjustments		670			(13		)	6,600			(6,054		)
Comprehensive income		$	3,661		$	8,210		$	25,648		$	18,453

 

13.   Acquisitions

On May 1, 2006, the Corporation completed the acquisition of Riley Medical, a privately-owned company based in Auburn, Maine, for approximately $45,740 in net cash, subject to adjustment. Riley Medical is a manufacturer of standard and custom cases, trays and containers for the medical device industry with locations in the United States and Switzerland.  The acquisition expands the Corporation’s geographic footprint in Europe and the case product line, including several new patents and trademarks.  Results of Riley Medical are included in the statement of operations from the acquisition date.

The aggregate purchase price is preliminary, subject to adjustment and expected to be finalized in the fourth fiscal quarter. As of September 30, 2006, the aggregate purchase price of $45,740 was allocated to the opening balance sheet as follows:

10

---

 

 

Unaudited Proforma Results  The following table represents the pro forma results of the Corporation’s operations had the acquisition of Riley Medical been completed as of the beginning of the periods presented.

		Three Months Ended						Nine Months Ended
		September 30,			October 1,			September 30,			October 1,
		2006			2005			2006			2005
Revenue		$	60,740		$	72,981		$	202,226		$	218,115
Income available to common shareholders		2,991			8,365			18,721			25,955
Earnings per share—basic		$	0.09		$	0.24		$	0.54		$	0.77
Earnings per share—diluted		$	0.09		$	0.24		$	0.53		$	0.75

 

On August 31, 2006, the Corporation completed the acquisition of Everest Metal, a privately-owned company, for approximately $8,802 in net cash, subject to adjustment and an earn-out provision. The earn-out provision may require payments of up to $400 at the end of 2006 and $1,000 at the end of 2007 if certain sales targets are met.  Everest Metal is an implant finishing operation with locations in the United States and Ireland. Everest Metal’s core competencies will accelerate the Corporation’s stated plan of growing its implant finishing operations and strengthening its local presence near its customers. Results of Everest Metal are included in the statement of operations from the acquisition date.

The aggregate purchase price is preliminary, subject to adjustment and an earn-out provision, and expected to be finalized in the fourth quarter. As of September 30, 2006, the aggregate purchase price of $8,802 was allocated to the opening balance sheet as follows:

 

11

ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Overview

We are the world’s largest independent provider of implants and related instruments and cases to orthopedic device manufacturers. We also design, develop and produce these products for companies in other segments of the medical device market, including dental, osteobiologic and endoscopy sectors, and provide limited specialized products and services to non-healthcare markets, primarily the aerospace industry.

We offer our customers Total Solution® for complete implant systems—implants, instruments and cases. While our revenue to date has been derived primarily from the sale of implants, instruments and cases separately, or instruments and cases together, our ability to provide Total Solutions for complete implant systems has already proven to be attractive to our customers, and we expect this capability will provide us with growth opportunities. In addition, we expect that our Total Solutions capability will increase the relative percentage of value added products that we supply to our customers. The expansion of our Design & Development Centers provides better Total Solutions management, increased prototyping capacity and increased engineering resources to drive our own product development and expand design services. We view our Design & Development Centers as a strategic competitive advantage.

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2005, provides additional information about our business, operations and financial condition.

On May 1, 2006, we completed the acquisition of Riley Medical, a privately-owned company based in Auburn, Maine, for $45.7 million in net cash, subject to adjustment. Riley Medical is a manufacturer of standard and custom cases, trays and containers for the medical device industry with locations in the United States and Switzerland. Riley Medical’s innovative case products, such as the Flashpak™, have been well received by our customers.  Riley Medical’s products have allowed us to realize a number of cross-selling synergies and additional market reach into markets such as spine and endoscopy.

On August 31, 2006, we completed the acquisition of Everest Metal, a privately-owned company, for approximately $8.8 million in net cash, subject to adjustment and an earn-out provision. The earn-out provision may require payments of up to $0.4 million at the end of 2006 and $1.0 million at the end of 2007 if certain sales targets are met.  Everest Metal is an implant finishing operation with locations in the United States and Ireland.  Everest Metal’s core competencies will accelerate our stated plan of growing our implant finishing operations and strengthening the local presence near our customers.

During the third quarter 2006, our revenue was impacted by the slowdown in demand for major orthopedic joints throughout the industry.  The orthopedic environment, from our perspective, went through a strong year of revenue growth in 2005 driven by a large volume of new customer product launches.  Procedure volumes and product mix were also favorable for our customers during this period.  In the first nine months of 2006, we saw a reduction in new product launches from our customers and slower growth on procedure volume for reconstructive joints.

As a key supplier to the original equipment manufactures in the orthopedic industry for these joints, we believe that we are disproportionately affected by these industry developments.  As our customers’ growth accelerates, we tend to grow faster and when their growth decelerates, we tend to slow down more rapidly.  These results were further impacted by a reduction in our customers’ product launches.  Fewer customer launches disproportionately impact our sales of instrument and cases as demand for these products is related to launches of new products.  While the current market conditions impact the entire supply chain, we remain confident that we will continue as the leading provider to the orthopedic market with implants, instruments and cases.  Further, we believe we remain well positioned to respond to an upturn in demand of the supply chain for the orthopedic industry.

We believe it is important to continue with the main strategic intent of our business and use our strength and market position.  We are taking advantage of this slower period to increase the productivity of our manufacturing sites and to extend our Total Solutions approach into other markets.  In particular, we continue to expand our engineering resources that produce and provide closer and critical customer relationships on the development of new products.  In addition, our focus on increasing revenue of finished implants to our current customers progressed in the quarter, aided by our acquisition of Everest Metal. We are developing our activities in Switzerland through the Riley Medical acquisition and are exploring opportunities in Asia to support our global expansion initiative. This local presence in the global marketplace allows us to be closer to our customer base, provide quicker response times and increase our value added services.

Third Quarter Results of Operations

Revenue.   Revenue for the three month period ended September 30, 2006 decreased $6.5 million, or 9.7%, to $60.7 million from $67.2 million for the comparable 2005 period.  Revenue for each of our principal product categories in these

12

---

periods was as follows:

 

		Three Months Ended
		September 30,			October 1,
Product Category		2006			2005
		(in millions)
Implants		$	23.3		$	28.2
Instruments		14.5			20.0
Cases		16.6			14.2
Other		6.3			4.8
Total		$	60.7		$	67.2

 

The $6.5 million reduction in revenue resulted from lower implant and instrument revenue of $4.9 million and $5.5 million respectively, as a result of the slowdown in demand for major orthopedic joints throughout the industry and major customers adjusting inventory levels of our products.  Because of our position in the supply chain for these joints, we are disproportionately affected by these industry developments.  These results were further impacted by a reduction in our customers’ product launches.  These reductions were partially offset by increased case sales of $2.4 million due to $5.4 million of sales from the Riley Medical acquisition. The Other category increase of $1.5 million was driven by the continued strength in the aerospace industry.

Gross Profit.   Gross profit for the three month period ended September 30, 2006 decreased $6.1 million, or 30.9%, to $13.6 million from $19.7 million for the comparable 2005 period. Gross margin was 22.5% for the three month period ended September 30, 2006 compared to 29.4% for the comparable 2005 period. The decline in gross margin as a percentage of sales was primarily driven by higher fixed costs from our significant investment in 2005 capacity expansion across our global facilities and a more pronounced sales reduction in our higher margin products within several of our product segments.  We view our global infrastructure as a competitive strength, and we have made a deliberate decision to keep our infrastructure in place, enabling us to respond quickly to our customers’ needs and produce high volume orders on short notice.

Selling, General and Administrative Expenses.   Selling, general and administrative expenses for the three month period ended September 30, 2006 decreased $0.1 million, or 0.6%, to $7.4 million from $7.5 million for the comparable 2005 period.  The 2006 period includes additional expenses of Riley Medical for the full quarter and Everest Metal expenses for one month, as well as $0.2 million of additional intangible asset amortization and an increase in expenses from costs related to additional stock compensation expenses. Despite these increased expenses, we were able to reduce costs across our global facilities so that total expenses decreased.  As a percentage of revenue, selling, general and administrative expenses still increased to 12.2% of revenue for the three month period ended September 30, 2006 from 11.1% of revenue for the comparable 2005 period due to the reduction in revenue.

Other Expense.   Interest expense for the three month period ended September 30, 2006 increased $0.7 million, or 112.6%, to $1.3 million from $0.6 million for the comparable 2005 period. This increase reflects the additional $40 million senior term debt related to the acquisition of Riley Medical.  This increase was partially offset by the reduction in outstanding capital lease obligations and existing senior term debt through normal amortization.  No additional borrowings were needed to complete the Everest Metal acquisition.

The derivatives valuation (gains) losses consist of interest rate swap valuations used to mitigate the effect of changing interest rates on net income and foreign currency forward contracts used to mitigate the effect of changes in the foreign exchange rates on net income. The increase in the loss of $1.3 million for the three month period ended September 30, 2006 versus the comparable 2005 period is due to market fluctuations in these contracts, which are not designated as hedges under SFAS 133.  $1.2 million of this loss related to the interest rate swap valuation.

Provision for Income Taxes.   Our effective tax rate was 21.6% for the three month period ended September 30, 2006 as compared to 23.8% for the comparable 2005 period. Provision for income taxes decreased by $1.8 million, or 67.8%, to $0.8 million for the three month period ended September 30, 2006 from $2.6 million for the comparable 2005 period. This decrease in rate was primarily due to a higher percentage of income coming from lower tax jurisdictions outside of the United States.  We did not record a Federal research and development tax credit in 2006 since the United States government has not yet reinstated Section 41 of the U.S. tax code.

Nine Months Results of Operations

Revenue.   Revenue for the nine month period ended September 30, 2006 decreased $6.1 million, or 3.0%, to $195.1 million from $201.2 million for the comparable 2005 period. Revenue for each of our principal product categories in these

13

---

periods was as follows:

 

		Nine Months Ended
		September 30,			October 1,
Product Category		2006			2005
		(in millions)
Implants		$	73.0		$	76.6
Instruments		54.1			67.9
Cases		47.8			43.8
Other		20.2			12.9
Total		$	195.1		$	201.2

 

The $6.1 million decrease in revenue resulted from decreased implant and instrument revenue of $3.6 million and $13.8 million, respectively, due to slower demand from customers as discussed in the Overview section.  These decreases were partially offset by increased case and other revenue.  Case revenue increased $4.0 million including $8.8 million from the Riley Medical acquisition. The other revenue increased $7.3 million due to continued strength in the aerospace industry.

Gross Profit.   Gross profit for the nine month period ended September 30, 2006 decreased $9.7 million, or 16.0%, to $50.9 million from $60.6 million for the comparable 2005 period. Gross margin was 26.1% for the nine month period ended September 30, 2006 compared to 30.1% for the comparable 2005 period. The decline in gross margin of 4.0% was primarily driven by higher fixed costs across our global facilities and a more pronounced sales reduction in our higher margin products within several of our product segments.  We view our global infrastructure as a competitive strength, and we have made a deliberate decision to keep our infrastructure in place, enabling us to respond quickly to our customers’ needs and produce high volume orders on short notice.

Selling, General and Administrative Expenses.   Selling, general and administrative expenses for the nine month period ended September 30, 2006 increased $0.1 million, or 0.9%, to $21.3 million from $21.2 million for the comparable 2005 period. While a number of initiatives to cut costs across our global facilities resulted in a reduction of costs, the addition of expenses related to the acquisitions of Riley Medical (for five months) and Everest Metal (for one month) drove a slight increase in our SG&A costs for the nine months.  We also had an increase in expenses primarily resulting from costs related to additional stock compensation expenses. As a percentage of revenue, selling, general and administrative expenses increased to 10.9% of revenue for the nine month period ended September 30, 2006 from 10.5% of revenue for the comparable 2005 period. This 0.4% increase as a percentage of revenue was attributable to the addition of Riley Medical and Everest Metal acquisitions partially offset by controlled spending on slightly lower sales.

Other Expense.   Interest expense for the nine month period ended September 30, 2006 increased $0.6 million, or 25.1%, to $2.9 million from $2.3 million for the comparable 2005 period. This increase primarily reflects the increase of interest from our $40 million new senior term debt from the Riley Medical acquisition offset by a decrease in outstanding capital lease obligations and previously held senior term debt.

The derivatives valuation (gains) losses consist of interest rate swap valuations used to mitigate the effect of changing interest rates on net income and foreign currency forward contracts used to mitigate the effect of changes in the foreign exchange rates on net income. The decrease in the gain for the nine month period ended September 30, 2006 versus the comparable 2005 period is due to market fluctuations in these contracts, which are not designated as hedges under SFAS 133.

Also included in Other is a $1.2 million gain on the sale of surplus land adjacent to our Sheffield, UK facility.  This resulted in an after tax gain of $0.8 million.

Provision for Income Taxes.   Provision for income taxes decreased by $2.5 million, or 23.5%, to $8.4 million for the nine month period ended September 30, 2006 from $10.9 million for the comparable 2005 period. Our effective tax rate was 30.5% for the nine month period ended September 30, 2006 as compared to 30.8% for the comparable 2005 period. This decrease of 0.3% was due primarily to the addition of the Indiana EDGE tax credit of $0.3, recorded in the second quarter of 2006, and a higher percentage of income coming from lower tax jurisdictions outside of the United States.

Liquidity and Capital Resources

Our principal sources of cash in the nine month period ended September 30, 2006 were cash generated from operations, borrowings under our senior credit term loan facility and U.K. revolving credit facility, proceeds from the sale of fixed assets (mainly sale of surplus land adjacent to our Sheffield, U.K. facility) and proceeds from the exercise of common stock options.

14

---

Principal uses of cash in the nine month period ended September 30, 2006 included working capital, capital expenditures, acquisitions and debt service. We expect that our principal uses of cash in the future will be to finance working capital, to pay for capital expenditures, to service debt and to fund potential mergers and acquisitions.

We completed the acquisition of Riley Medical on May 1, 2006 for $45.7 million, subject to adjustment, through the use of the existing cash balances and a $40.0 million senior debt facility.  We also completed the acquisition of Everest Metal on August 31, 2006 for $8.8 million, subject to adjustment and an earn-out provision, through the use of existing cash balances.

Operating Activities   We generated cash from operations of $25.4 million in the nine month period ended September 30, 2006 compared to $34.6 million for the nine month period ended October 1, 2005, which is a decrease of $10.2 million. The decrease in cash from operations is primarily a result of the decrease in net income of $5.5 million combined with the decrease cash flow from working capital of $4.7 million for the comparable periods. Cash provided by operating activities in the nine month period ended September 30, 2006 is primarily the result of a $31.5 million in net income, adjusted for non-cash items, such as depreciation expense and the derivative valuation change, offset by increases in net working capital.

Uses of cash due to changes in working capital were $6.1 million in the nine month period ended September 30, 2006.  The primary uses of cash for working capital came from an increase in inventory of $1.7 million and decreases in accounts payable and accrued expenses of $7.6 million. A portion of the decrease in accounts payable was due to lower volume and lower capital expenditure purchases and a portion of the decrease in accrued expenses was due to reduction of performance bonus accruals.

Investing Activities   Capital expenditures decreased by $15.5 million, or 49.5%, in the nine month period ended September 30, 2006 compared to the nine month period ended October 1, 2005.  The Riley Medical and Everest Metal acquisitions accounted for a $54.5 million use of cash in 2006.  We also sold a portion of land that was not needed for expansion near our Sheffield, United Kingdom facility for approximately $2.4 million in the second quarter of 2006.

Financing Activities   Financing activities generated $39.5 million of cash due primarily to the $40.0 million term loan obtained in conjunction with the Riley Medical acquisition.

Capital Expenditures

Capital expenditures totaled $15.8 million for the nine months ended September 30, 2006, compared to $31.4 million for the nine month period ended October 1, 2005. Expenditures were primarily used to complete our new design and development facility in Warsaw, Indiana, expand our Sheffield, U.K. facility for increased forge and machining capacity for the aerospace products, and maintain production capacity in all of our production facilities.

Debt and Credit Facilities

In connection with our May 2006 acquisition of Riley Medical, we entered into a $40.0 million senior secured five-year term loan. As part of an amendment and restatement of our senior credit facility, we negotiated a 25 basis point interest rate reduction for all of our outstanding senior debt.

As of September 30, 2006, we had an aggregate of $77.9 million of outstanding indebtedness, which consisted of $64.2 million of term loan borrowings outstanding under our senior credit facility, no borrowings outstanding under our revolving credit facility, $4.7 million of borrowings under our U.K. short-term credit facility and $9.0 million of capital lease obligations. We had no outstanding letters of credit as of September 30, 2006.  We have prepaid our scheduled senior term loan payments through the first quarter of 2007.

Our senior credit agreement contains various financial covenants, including covenants requiring a maximum total debt to EBITDA ratio, minimum EBITDA to interest ratio and a minimum EBITDA to fixed charges ratio. We were in compliance with our financial and restrictive covenants under the senior credit facility as of September 30, 2006.

We believe that cash flow from operating activities and borrowings under our senior credit facility will be sufficient to fund currently anticipated working capital, planned capital spending, debt service requirements for the foreseeable future, including at least the next twelve months. We also review technology, manufacturing and other strategic acquisition opportunities regularly, which may require additional debt or equity financing.

Contractual Obligations and Commercial Commitments

The following table reflects our contractual obligations as of September 30, 2006:

15

---

 

		Payments due by period
		Total			Less than 1 year*			1-3 years			3-5 years			More than 5 years
		(in millions)
Long-term debt obligations (1)		$	64.2		$	—		$	14.7		$	22.3		$	27.2
Capital lease obligations		13.7			1.0			6.0			2.1			4.6
Operating lease obligations		5.1			0.4			2.4			1.4			0.9
Purchase obligations (2)		37.2			5.7			15.7			10.5			5.3
Total		$	120.2		$	7.1		$	38.8		$	36.3		$	38.0

 

*                 Less than 1 year is defined as the remainder of fiscal 2006. Following periods are whole fiscal years.

(1)        Represents principal maturities only and, therefore, excludes the effects of interest and interest rate swaps.  We have prepaid $3.3 million in term debt as of September 30, 2006.

(2)        Represents purchase agreements to buy minimum quantities of titanium and cobalt chrome through December 2007.  The titanium contract disclosed in our Annual Report on Form 10-K has been modified and additional titanium and cobalt chrome contracts have been entered into in the second quarter of 2006.  Also represents a purchase agreement to buy Radel® R, a specialized plastic used in cases, through December 2011.

Off-Balance Sheet Arrangements

Our off-balance sheet arrangements and contractual obligations include our operating leases and letters of credit. There have been no material changes from the information provided in our Annual Report on Form 10-K for fiscal year ended December 31, 2005.

Environmental

There have been no material changes from the information provided in our Annual Report on Form 10-K for fiscal year ended December 31, 2005.

Critical Accounting Policies and Estimates

The preparation of our financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. Our Annual Report on Form 10-K for fiscal year ended December 31, 2005 includes a summary of the critical accounting policies we believe are the most important to aid in understanding its financial results. There have been no material changes to these critical accounting policies that impacted our reported amounts of assets, liabilities, revenues or expenses during the nine months ended September 30, 2006.

New Accounting Pronouncements

We adopted SFAS 123 (revised 2004), Share-Based Payment on January 1, 2006 (SFAS 123R). SFAS 123R, which revised SFAS 123, Accounting for Stock-Based Compensation, superseded APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends SFAS 95, Statement of Cash Flows. Statement 123R requires that all share-based payments to employees, including grants of employee stock options be recognized in the financial statements based upon their fair value. We had previously followed APB No. 25 in accounting for our stock options and accordingly, no compensation cost had been previously recognized.

We have adopted SFAS 123R using the modified prospective method. Compensation cost has been recognized for all share-based payments in the consolidated financial statements in 2006 based upon the fair value of the stock or option grant. Prior period results have not been restated.

As a result of adopting SFAS 123R, our income before income taxes and net income for the nine months ended September 30, 2006 are $92 and $55 lower, respectively, than if we had continued to account for share-based compensation under Opinion 25. Basic and diluted earnings per share for the nine months ended September 30, 2006 would not have changed from $0.55 and $0.54, respectively, if we had not adopted SFAS 123R.

Prior to the adoption of SFAS 123R, we presented all tax benefits of deductions resulting from the exercise of stock options as operating cash flows in the Consolidated Statements of Cash Flows. SFAS 123R requires the cash flows resulting from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options (excess tax

16

---

benefits) to be classified as financing cash flows. The $1.1 million excess tax benefit classified as a financing cash inflow would have been classified as an operating cash inflow if we had not adopted SFAS 123R.

Statement 123, as amended, required pro forma presentation as if compensation costs had been expensed under the fair value method. For purpose of pro forma disclosure, the estimated fair value of stock options at the grant date is amortized to expense over the vesting period.

In July 2006, the FASB issued FASB Interpretation No. (FIN) 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109, which clarifies the accounting for uncertainty in tax positions. This Interpretation requires the recognition of a tax position when it is more likely than not that the tax position will be sustained upon examination by relevant taxing authorities, based on the technical merits of the position. The provisions of FIN 48 are effective for us on January 1, 2007, with the cumulative effect of the change in accounting principle recorded as an adjustment to opening retained earnings. We are currently evaluating the impact of adopting FIN 48 on the financial statements.

Cautionary Notice Regarding Forward-Looking Statements

Certain statements contained in this Quarterly Report on Form 10-Q and other written and oral statements made from time to time by the Corporation do not relate strictly to historical or current facts. As such they are considered “forward-looking statements” that provide current expectations or forecasts of future events. Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “could,” “estimate,” “intend” and similar words, although some forward-looking statements are expressed differently. Factors that could cause the Corporation’s actual results to differ materially from the expectations expressed in our forward-looking statements include, but are not limited to, the following: changes in general economic conditions in the United States and Europe; our ability to retain existing customers, particularly our key customers, and attract new customers; the timing of significant orders and shipments, including the effects of changes in inventory management practices by our customers; the competitive nature of the orthopedic device market; the pursuit of strategic acquisitions or encountering unforeseen difficulties in integrating acquisitions; the degree to which we are leveraged and our significant debt service obligations; the impact of work stoppages and other labor matters; general economic or business conditions affecting the orthopedic device market being less favorable than expected; our ability to anticipate changes in technology and regulatory standards and to successfully develop and introduce new and enhanced products on a timely basis; the unpredictability of intellectual property protection and maintenance and other intellectual property issues; any future changes in management or loss of key personnel; unforeseen problems associated with international sales and operations, including gains and losses from foreign currency exchange; product liability lawsuits brought against us or our customers; implementation of or changes in laws, regulations or policies that could negatively affect the orthopedic device market; and other uncertainties and factors discussed in the “Risk Factors” section of the Corporation’s Annual Report on Form 10-K filed on February 27, 2006, elsewhere in this Quarterly Report on Form 10-Q and in the Corporation’s other filings with the Securities and Exchange Commission.

Forward-looking statements relate only to events as of the date on which the statements are made. Except as required by law, the Corporation’s undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, even if new information becomes available in the future.

ITEM 3.                          QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

For financial market risks related to changes in interest rates, foreign currency exchange rates, commodity prices and the effects of inflation, reference is made to Item 7a “Quantitative and Qualitative Disclosures About Market Risk” contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2005. Our exposure to these risks has not changed materially since December 31, 2005.

ITEM 4.                          CONTROLS AND PROCEDURES

(a)    Evaluation of disclosure controls and procedures.

Our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934), have concluded that, as of the end of the fiscal quarter covered by this report on Form 10-Q, our disclosure controls and procedures were adequate and designed to ensure that material information relating to the Corporation and its consolidated subsidiaries would be made known to them by others within those entities.

(b)    Changes in internal control over financial reporting.

During the quarter, there have been no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f)

17

---

of the Securities Exchange Act of 1934) that occurred during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except that we are still in the process of integrating the Riley Medical and Everest Metal operations and will be incorporating these operations as part of our internal controls. For purposes of this evaluation, the impact of these acquisitions on our internal controls over financial reporting has been excluded. See Note 13 to the condensed consolidated financial statements included in Item 1 for a discussion of the Riley Medical and Everest Metal acquisitions.

PART II   OTHER INFORMATION

ITEM 1                             LEGAL PROCEEDINGS

None.

ITEM 1A                    RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2005, which could materially affect our business, financial condition or future results. The Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005 have not materially changed.

ITEM 2                             RECENT SALES OF UNREGISTERED SECURITIES; USE OF PROCEEDS FROM REGISTERED SECURITIES

On September 29, 2006, Olympus Growth Fund III, L.P. converted warrants to purchase 88,282 shares of the Corporation’s common stock into 88,223 shares of the Corporation’s common stock.

The above issuance of shares of the Corporation’s common stock upon the conversion or exercise of warrants on September 29, 2006 was made in reliance on the exemptions provided by Section 3(a)(9) and 4(2) of the Securities Act of 1933.

ITEM 5                             OTHER INFORMATION

(b)       There have been no material changes to the procedures by which security holders may recommend nominees to our Board of Directors since our Schedule 14A filed March 21, 2006.

ITEM 6                             EXHIBITS

10.24		Asset Purchase Agreement, dated August 31, 2006, between Symmetry Medical USA Inc. and Everest Metal Finishing LLC and Christopher W. Huntington, Phillip Milidantri, and Levi Citarella (incorporated by reference to Exhibit 10.1 from our Form 8-K filed on September 9, 2006).
10.25		Stock Purchase Agreement, dated August 31, 2006, between Symmetry Medical International Inc. and Christopher W. Huntington, Phillip Milidantri, and Levi Citarella (incorporated by reference to Exhibit 10.2 from our Form 8-K, filed September 9, 2006).
31.1		Certification of Chief Executive Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		SYMMETRY MEDICAL INC.
		By	/s/ BRIAN MOORE
			Brian Moore,
			President and Chief Executive Officer
			(Principal Executive Officer)
		By	/s/ FRED HITE
			Fred Hite,
			Senior Vice President and Chief Financial Officer
			(Principal Financial and Accounting Officer)

 

November 8, 2006

19